藥明康德榮膺弗若斯特沙利文“2025全球CRDMO年度公司獎(jiǎng)” | Bilingual News

2025年11月20日 —藥明康德今日宣布公司憑借獨(dú)特的一體化CRDMO模式，榮獲全球增長(zhǎng)咨詢機(jī)構(gòu)弗若斯特沙利文（Frost & Sullivan）頒發(fā)的“2025全球CRDMO年度公司獎(jiǎng)”。這是藥明康德連續(xù)第九年獲得該機(jī)構(gòu)的認(rèn)可，彰顯了公司在賦能創(chuàng)新與卓越運(yùn)營(yíng)等方面持續(xù)取得的突出成就。

弗若斯特沙利文高度評(píng)價(jià)了公司一體化、端到端的CRDMO模式推動(dòng)了科學(xué)與技術(shù)創(chuàng)新，助力全球客戶加速新藥研發(fā)進(jìn)程，讓創(chuàng)新療法早日上市惠及患者。弗若斯特沙利文指出，藥明康德具有前瞻的戰(zhàn)略視野，始終跟隨科學(xué)的發(fā)展，不斷布局新能力，并以客戶為中心，建立了高標(biāo)準(zhǔn)的質(zhì)量體系。公司的CRDMO模式貫穿新藥研發(fā)價(jià)值鏈，消除了各階段研發(fā)項(xiàng)目銜接的風(fēng)險(xiǎn)，確保了連續(xù)性、合規(guī)性和質(zhì)量標(biāo)準(zhǔn)化。通過(guò)持續(xù)建設(shè)多肽、寡核苷酸及復(fù)雜偶聯(lián)物等新分子能力，藥明康德已成為生命科學(xué)領(lǐng)域前沿創(chuàng)新的重要推動(dòng)者。公司的全球網(wǎng)絡(luò)覆蓋亞洲、歐洲和北美，能夠?yàn)樾屡d生物科技公司、跨國(guó)藥企等各類客戶提供量身定制的服務(wù)，借助專業(yè)知識(shí)和全球基地的支持，賦能客戶更快、更有效地將創(chuàng)新療法推向市場(chǎng)。

“藥明康德憑借獨(dú)特的CRDMO業(yè)務(wù)模式在全球生命科學(xué)行業(yè)中脫穎而出。”弗若斯特沙利文副總裁Unmesh Lal表示，“該模式實(shí)現(xiàn)了從藥物研究、開發(fā)、到生產(chǎn)的全流程無(wú)縫銜接，幫助客戶降低風(fēng)險(xiǎn)，提高效率并加速商業(yè)化進(jìn)程。藥明康德具備科學(xué)創(chuàng)新與極致運(yùn)營(yíng)的能力，支持全球創(chuàng)新者將概念轉(zhuǎn)化為切實(shí)有效的療法。”

“藥明康德非常榮幸再次獲得弗若斯特沙利文全球CRDMO年度公司獎(jiǎng)。”藥明康德董事長(zhǎng)兼首席執(zhí)行官李革博士表示，“這充分展現(xiàn)了藥明康德全球團(tuán)隊(duì)持續(xù)通過(guò)CRDMO平臺(tái)賦能客戶加速新藥研發(fā)的堅(jiān)定承諾。我們將繼續(xù)聚焦CRDMO核心戰(zhàn)略，不斷加速平臺(tái)能力建設(shè)和產(chǎn)能投放，助力更多新藥、好藥早日問(wèn)世，造福全球病患。”

弗若斯特沙利文每年評(píng)選“年度公司獎(jiǎng)”，授予那些在戰(zhàn)略發(fā)展與落地執(zhí)行中表現(xiàn)出色，并在市場(chǎng)份額、客戶滿意度及競(jìng)爭(zhēng)力方面取得實(shí)質(zhì)提升的企業(yè)。

關(guān)于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫(yī)藥及生命科學(xué)行業(yè)值得信賴的合作伙伴和重要貢獻(xiàn)者，致力于通過(guò)提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，推動(dòng)全球醫(yī)藥健康創(chuàng)新。公司在亞洲、歐洲、北美等地均設(shè)有運(yùn)營(yíng)基地，依托獨(dú)特的“CRDMO”業(yè)務(wù)模式，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率，為患者帶來(lái)突破性的治療方案。目前，公司的賦能平臺(tái)正承載著來(lái)自全球30多個(gè)國(guó)家的約6,000家合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒(méi)有難做的藥，難治的病”的愿景。

WuXi AppTec Receives Frost & Sullivan’s 2025 Global Company of the Year Award in the CRDMO Industry

November 19, 2025 - WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has been recognized by Frost & Sullivan with the 2025 Global Company of the Year Award in the CRDMO industry. This marks the ninth consecutive year that WuXi AppTec has received this distinguished honor, underscoring the company’s ongoing achievements in enabling innovation and operational excellence for its customers.

Frost & Sullivan’s recognition highlights WuXi AppTec’s integrated, end-to-end CRDMO model, which drives scientific and technological advancement and enables customers and partners worldwide to accelerate drug development and deliver transformative therapies efficiently.

According to Frost & Sullivan, WuXi AppTec has established a robust foundation of scientific capability, quality, and customer-focused agility through its forward-looking growth strategy. The company’s unified CRDMO model eliminates handoffs between stages of development, supporting continuity, quality, and compliance across the value chain. By continuously investing in next-generation technologies like complex peptides, oligonucleotides and novel conjugates, WuXi AppTec is a catalyst for innovation in the life sciences. With footprint across Asia, Europe, and North America, WuXi AppTec delivers tailored support for customers ranging from emerging biotech firms to pharmaceutical multinationals, ensuring fast access to specialized expertise and a global infrastructure to bring therapies to market faster and more efficiently.

“WuXi AppTec’s integrated CRDMO platform continues to redefine what strategic partnership means in the pharmaceutical ecosystem,” said Unmesh Lal, Vice President at Frost & Sullivan. “Its ability to seamlessly connect discovery, development, and manufacturing allows clients to reduce risk, improve efficiency, and accelerate commercialization timelines. WuXi AppTec stands out for combining scientific depth with operational excellence, helping global innovators transform complex ideas into life-saving realities.”

“It is an honor to again receive Frost & Sullivan’s 2025 Global Company of the Year Award,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “This recognition underscores the commitment of our global teams and our shared commitment to enabling customers to advance medicines through our integrated CRDMO platform. We will continue to focus on our core CRDMO strategy, and on expansion of our global capabilities and capacity to help our customers bring life-changing therapies to patients faster and more efficiently.”

Each year, Frost & Sullivan presents the Company of the Year Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場(chǎng)，亦不代表藥明康德支持或反對(duì)文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請(qǐng)前往正規(guī)醫(yī)院就診。

版權(quán)說(shuō)明：歡迎個(gè)人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺(tái)。轉(zhuǎn)載授權(quán)請(qǐng)?jiān)凇杆幟骺档隆刮⑿殴娞?hào)回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。